146 related articles for article (PubMed ID: 37394317)
1. Role of hyperglycemia in cystic fibrosis pulmonary exacerbations.
Merjaneh L; Sidhaye AR; Vu PT; Heltshe SL; Goss CH; Flume PA; Kelly A; Rosenfeld M
J Cyst Fibros; 2023 Sep; 22(5):868-874. PubMed ID: 37394317
[TBL] [Abstract][Full Text] [Related]
2. Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF.
Scully KJ; Brenner L; Martin K; Ruazol M; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Putman MS
Front Endocrinol (Lausanne); 2024; 15():1293709. PubMed ID: 38379863
[TBL] [Abstract][Full Text] [Related]
3. Continuous glucose monitoring indices predict poor FEV
Pallin M; Kumar S; Daley C; Dawadi S; Leong P; Carr E; Soldatos G
J Cyst Fibros; 2021 Sep; 20(5):785-791. PubMed ID: 33781701
[TBL] [Abstract][Full Text] [Related]
4. Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.
Scully KJ; Sherwood JS; Martin K; Ruazol M; Marchetti P; Larkin M; Zheng H; Sawicki GS; Uluer A; Neuringer I; Yonker LM; Sicilian L; Wexler DJ; Putman MS
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1444-e1454. PubMed ID: 34850006
[TBL] [Abstract][Full Text] [Related]
5. Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations.
Merjaneh L; Toprak D; McNamara S; Nay L; Sullivan E; Rosenfeld M
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00208. PubMed ID: 33855211
[TBL] [Abstract][Full Text] [Related]
6. Continuous glucose monitoring in a cystic fibrosis patient to predict pulmonary exacerbation?
Inman TB; Proudfoot JA; Lim M; Demeterco-Berggren C
J Cyst Fibros; 2017 Sep; 16(5):628-630. PubMed ID: 28625799
[TBL] [Abstract][Full Text] [Related]
7. Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome?
Zorron M; Marson FAL; Morcillo AM; Gonçalves AC; El Beck MS; Ribeiro JD; Ribeiro AF
J Bras Pneumol; 2022; 48(2):e20210307. PubMed ID: 35475864
[TBL] [Abstract][Full Text] [Related]
8. Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline.
Chan CL; Vigers T; Pyle L; Zeitler PS; Sagel SD; Nadeau KJ
J Cyst Fibros; 2018 Nov; 17(6):783-790. PubMed ID: 29580828
[TBL] [Abstract][Full Text] [Related]
9. Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes.
Taylor-Cousar JL; Janssen JS; Wilson A; Clair CG; Pickard KM; Jones MC; Brayshaw SJ; Chacon CS; Barboa CM; Sontag MK; Accurso FJ; Nichols DP; Saavedra MT; Nick JA
J Diabetes Res; 2016; 2016():1527932. PubMed ID: 27999822
[No Abstract] [Full Text] [Related]
10. Drug treatments for managing cystic fibrosis-related diabetes.
Onady GM; Stolfi A
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD004730. PubMed ID: 33075159
[TBL] [Abstract][Full Text] [Related]
11. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
12. Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes.
Karter AJ; Parker MM; Moffet HH; Gilliam LK; Dlott R
JAMA; 2021 Jun; 325(22):2273-2284. PubMed ID: 34077502
[TBL] [Abstract][Full Text] [Related]
13. Oral glucose tolerance test and continuous glucose monitoring to assess diabetes development in cystic fibrosis patients.
Clemente León M; Bilbao Gassó L; Moreno-Galdó A; Campos Martorrell A; Gartner Tizzano S; Yeste Fernández D; Carrascosa Lezcano A
Endocrinol Diabetes Nutr (Engl Ed); 2018 Jan; 65(1):45-51. PubMed ID: 29137964
[TBL] [Abstract][Full Text] [Related]
14. The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis.
Scully KJ; Marchetti P; Sawicki GS; Uluer A; Cernadas M; Cagnina RE; Kennedy JC; Putman MS
J Cyst Fibros; 2022 Mar; 21(2):258-263. PubMed ID: 34531155
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemia is common in children with cystic fibrosis and seen predominantly in females.
Haliloglu B; Gokdemir Y; Atay Z; Abali S; Guran T; Karakoc F; Ersu R; Karadag B; Turan S; Bereket A
Pediatr Diabetes; 2017 Nov; 18(7):607-613. PubMed ID: 27873431
[TBL] [Abstract][Full Text] [Related]
16. Early glucose abnormalities revealed by continuous glucose monitoring associate with lung function decline in cystic fibrosis: A five-year prospective study.
Rakotoarisoa L; Weiss L; Lefebvre F; Porzio M; Renaud-Picard B; Ravoninjatovo B; Abely M; Danner-Boucher I; Dubois S; Troussier F; Prevotat A; Rault G; Kessler R; Kessler L
J Diabetes Complications; 2024 Apr; 38(4):108703. PubMed ID: 38430625
[TBL] [Abstract][Full Text] [Related]
17. Reliability of Inpatient CGM: Comparison to Standard of Care.
Price C; Ditton G; Russell GB; Aloi J
J Diabetes Sci Technol; 2023 Mar; 17(2):329-335. PubMed ID: 34911384
[TBL] [Abstract][Full Text] [Related]
18. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
[TBL] [Abstract][Full Text] [Related]
19. The Role of Continuous Glucose Monitoring in Detecting Early Dysglycemia and Clinical Outcomes in Patients with Cystic Fibrosis.
Kirigin Biloš LS; Altabas V; Vukić Dugac A; Baretić M
Medicina (Kaunas); 2024 Mar; 60(3):. PubMed ID: 38541202
[TBL] [Abstract][Full Text] [Related]
20. MARKEDLY DELAYED INSULIN SECRETION AND A HIGH RATE OF UNDETECTED OVERT DIABETES CHARACTERIZE GLUCOSE METABOLISM IN ADULT PATIENTS WITH CYSTIC FIBROSIS AFTER LUNG TRANSPLANTATION.
Winhofer Y; Wolf P; Fellinger P; Tura A; Hillebrand P; Staufer K; Trauner M; Jaksch P; Muraközy G; Kautzky-Willer A; Pacini G; Krebs M; Luger A; Kazemi-Shirazi L
Endocr Pract; 2019 Mar; 25(3):254-262. PubMed ID: 30913015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
